Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2021 | The FLEX database is expediting genomic discoveries in breast cancer

Miranda Kleijn • 25 Mar 2021
BCC 2021
Breast Cancer
FLEX

Miranda Kleijn, PhD, Agendia, Amsterdam, Netherlands, discusses the FLEX study (NCT03053193), a large-scale, prospective, observational trial of patients with stage I-III breast cancer. FLEX aims to create a global registry that links comprehensive clinical and full genome expression data to elucidate new prognostic and/or predictive gene associations. The dataset will record linked genomic and clinical data, with over 800 data points for each patient over a 10-year follow-up period. Over 6000 patients are registered to date, with continuing enrollment worldwide. FLEX investigator-initiated substudies have resulted in 18 published abstracts. The real-world dataset brings great opportunities for novel genomic discoveries to aid the growth of precision oncology. This interview took place during the 17th St. Gallen International Breast Cancer Conference.

More from Miranda Kleijn

5-year DMFS outcomes in the NBREaST II trial
2:19
5-year DMFS outcomes in the NBREaST II trial
Miranda Kleijn • 25 Mar 2021
Genomic testing in early breast cancer: MammaPrint & BluePrint
2:00
Genomic testing in early breast cancer: MammaPrint & BluePrint
Miranda Kleijn • 25 Mar 2021
Genomic assay performance: core needle biopsy vs. surgical resection samples
2:19
Genomic assay performance: core needle biopsy vs. surgical resection samples
Miranda Kleijn • 25 Mar 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals